Beijing Science Sun Pharmaceutical Co (SZSE:300485) Total Liabilities : ¥134.9 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Beijing Science Sun Pharmaceutical Co Total Liabilities?

Beijing Science Sun Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥134.9 Mil.

Beijing Science Sun Pharmaceutical Co's quarterly Total Liabilities increased from Sep. 2023 (¥139.27 Mil) to Dec. 2023 (¥154.61 Mil) but then declined from Dec. 2023 (¥154.61 Mil) to Mar. 2024 (¥134.94 Mil).

Beijing Science Sun Pharmaceutical Co's annual Total Liabilities increased from Dec. 2021 (¥118.54 Mil) to Dec. 2022 (¥157.10 Mil) but then declined from Dec. 2022 (¥157.10 Mil) to Dec. 2023 (¥154.61 Mil).

Beijing Science Sun Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Beijing Science Sun Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Science Sun Pharmaceutical Co Total Liabilities Chart

Beijing Science Sun Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

94.26

141.13

118.54

157.10

154.61

Beijing Science Sun Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															136.70	156.00	139.27	154.61	134.94

Beijing Science Sun Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Beijing Science Sun Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	51.448	+	(0	+	103.162
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	154.6

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	3622.202	-	3467.591
	=	154.6

Beijing Science Sun Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	67.136	+	(0	+	67.806
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	134.9

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3410.25	-	3275.307
	=	134.9

Beijing Science Sun Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Beijing Science Sun Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Science Sun Pharmaceutical Co (SZSE:300485) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing Science Sun Pharmaceutical Co Ltd (SZSE:300485) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

No. 8, Xingsheng Street, Yizhuang Economic and Technological Development Zone, Beijing, CHN, 100176

Website

http://www.ssyy.com.cn

Beijing Science Sun Pharmaceutical Co Ltd is engaged in the research and development, production and sales of biological drugs. The company products can be divided into cardiovascular series, immune regulation series, nervous system series, and other natural or biotech pharmaceuticals. Its products include Injection Tiopronin, Cybex, Xel, Lichinga, Plasmin Injection and Race liter.

Executives

Ma Li	Directors, executives
Kong Shuang Quan	Executives
Li Jian Hua	Director
Ma Biao	Directors, executives
Li Zhi Bing	Supervisors
Zhang Fan	Executives

Beijing Science Sun Pharmaceutical Co (SZSE:300485) Headlines

No Headlines